EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Clinical Impact of the CYP2C19 Gene on Diazepam for the Management of Alcohol Withdrawal Syndrome

Teresa T Ho iD, Melissa Noble, Bao Anh Tran, Katlynd Sunjic, Sheeba Varghese Gupta, Jacques Turgeon iD, Rustin D Crutchley iD

Journal of Personalized Medicine · 03.02.2023 · 13 (2) · 285

DOI: 10.3390/jpm13020285 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Personalized Medicine, online erschienen am 03.02.2023. Verfasst von Teresa T Ho und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacotherapeutics & Clinical Research, University of South Florida Taneja College of Pharmacy, Tampa, FL 33612, USA. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Diazepam is a benzodiazepine widely prescribed for the management of patients with severe alcohol withdrawal syndrome to prevent agitation, withdrawal seizures, and delirium tremens. Despite standard dosing of diazepam, a subset of patients experience refractory withdrawal syndromes or adverse drug reactions, such as impaired motor coordination, dizziness, and slurred speech. The CYP2C19 and CYP3A4 enzymes play a key role in the biotransformation of diazepam. Given the highly polymorphic nature of the CYP2C19 gene, we reviewed the clinical impact of variants in the CYP2C19 gene on both the pharmacokinetics of diazepam and treatment outcomes related to the management of alcohol withdrawal syndrome.

Schlagwörter

Stichwörter der Autor:innen

CYP2C19alcohol withdrawal syndromebenzodiazepinesdiazepampersonalized medicinepharmacogenomics

Autor:innen und Institutionen

  • Department of Pharmacotherapeutics & Clinical Research, University of South Florida Taneja College of Pharmacy, Tampa, FL 33612, USA.
  • Department of Pharmaceutical Sciences, University of South Florida College of Pharmacy, Tampa, FL 33612, USA.
  • Precision Pharmacotherapy Research & Development Institute, Tabula Rasa HealthCare, Moorestown, NJ 08057, USA.
  • Department of Pharmacotherapy, Washington State University, College of Pharmacy and Pharmaceutical Sciences, Yakima, WA 98901, USA.

ORCID-Profile: Teresa T Ho, Jacques Turgeon, Rustin D Crutchley

Zitieren

APA

Ho, T. T., Noble, M., Tran, B. A., Sunjic, K., Gupta, S. V., Turgeon, J., & Crutchley, R. D. (2023). Clinical Impact of the CYP2C19 Gene on Diazepam for the Management of Alcohol Withdrawal Syndrome. Journal of Personalized Medicine, 13(2), 285. https://doi.org/10.3390/jpm13020285

Vancouver

Ho TT, Noble M, Tran BA, Sunjic K, Gupta SV, Turgeon J, et al. Clinical Impact of the CYP2C19 Gene on Diazepam for the Management of Alcohol Withdrawal Syndrome. Journal of Personalized Medicine. 2023;13(2):285. doi:10.3390/jpm13020285

BibTeX
@article{Ho2023,
  author = {Ho, Teresa T and Noble, Melissa and Tran, Bao Anh and Sunjic, Katlynd and Gupta, Sheeba Varghese and Turgeon, Jacques and Crutchley, Rustin D},
  title = {Clinical Impact of the CYP2C19 Gene on Diazepam for the Management of Alcohol Withdrawal Syndrome},
  journal = {Journal of Personalized Medicine},
  year = {2023},
  volume = {13},
  number = {2},
  pages = {285},
  doi = {10.3390/jpm13020285}
}
Kostenlos starten →